Core Insights - Roche has announced a strategic collaboration with Broad Clinical Labs to develop applications using its next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology, aiming to transform clinical genomics and biomedical discovery [1][5] - The initial project will focus on trio-based whole genome sequencing for critically ill newborns and their biological parents, with the goal of integrating whole genome sequencing into routine clinical care in neonatal intensive care units (NICUs) [2][8] - The SBX technology is designed for fast, scalable sequencing solutions, offering ultra-fast turnaround times, exceptional scalability, and cost efficiency, making it suitable for various genomic applications [3][9] Company Overview - Roche is a leading biotechnology company and global leader in in-vitro diagnostics, founded in 1896, with a commitment to advancing precision medicine and improving healthcare outcomes [12] - Broad Clinical Labs, a subsidiary of the Broad Institute of MIT and Harvard, specializes in human whole genome sequencing and has sequenced over 750,000 genomes, focusing on understanding and diagnosing human diseases [11] Technology Highlights - The SBX technology offers high-throughput performance with a flexible workflow, enabling rapid deployment in time-sensitive settings like NICUs and supporting comprehensive multi-omic discovery research [3][4] - It includes advanced, high-throughput CMOS sensor modules that allow for ultra-rapid, real-time base calls and analysis, enhancing scalability and flexibility for various project sizes [7][9] - The collaboration will also explore RNA sequencing capabilities, leveraging longer reads of the SBX technology to gain novel molecular insights and identify new therapeutic targets [4][9]
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology